TP53 and pancreatic neoplasm: No significant differences were obvious for the biomarker results based on clinical characteristics; of note, although the numbers were small, all 4 patients with a p53 loss had a good pre-treatment performance status and 2 of them (50%) had locally advanced disease (whereas in patients with regular p53 expression only 5% had locally advanced pancreatic cancer).